Heterozygous familial hypercholesterolaemia : the influence of the mutation type of the low-density-lipoprotein receptor gene and PvuII polymorphism of the normal allene on serum lipid levels and response to lovastatin treatmentVUORIO, A. F; OJALA, J.-P; SARNA, S et al.Journal of internal medicine. 1995, Vol 237, Num 1, pp 43-48, issn 0954-6820Article

Treatment of combined hyperlipidemia with lovastatin versus Gemfibrozil : a comparison studyOJALA, J.-P; HELVE, E; TIKKANEN, M. J et al.Cardiology. 1990, Vol 77, pp 39-49, issn 0008-6312, 11 p., SUP4Conference Paper

Lovastatin and gemfibrozil in the treatment of type 2a and type 2b hyperlipoproteinemiaTIKKANEN, M. J; OJALA, J.-P; HELVE, E et al.European journal of clinical pharmacology. 1991, Vol 40, pp S23-S25, issn 0031-6970, SUP1Conference Paper

Serum ubiquinone concentrations after short- and long-term treatment with HMG-Coa reductase inhibitorsLAAKSONEN, R; OJALA, J.-P; TIKKANEN, M. J et al.European journal of clinical pharmacology. 1994, Vol 46, Num 4, pp 313-317, issn 0031-6970Article

Non-cholesterol sterols and faecal elimination of cholesterol during statin and fibrate treatmentMIETTINEN, T. A; VANHANEN, H; OJALA, J.-P et al.Atherosclerosis. 1992, Vol 97, pp S73-S80, issn 0021-9150, SUPConference Paper

Screening of the 3' two-thirds of the coding area of the apo B gene in Finnish hypercholesterolemic patients : Report of six new genetic variantsILMONEN, M; EBELING, T; VIIKARI, J et al.Atherosclerosis. 1997, Vol 128, Num 2, pp 191-199, issn 0021-9150Conference Paper

Long-term use of lovastatin in different types of hyperlipidaemiaTIKKANEN, M. J; OJALA, J.-P; HELVE, E et al.Atherosclerosis. 1992, Vol 97, pp S27-S32, issn 0021-9150, SUPConference Paper

Use of polymerase chain reaction to defect heterozygous familial hypercholesterolemiaKEINAÊNEN, M; OJALA, J.-P; HELVE, E et al.Clinical chemistry (Baltimore, Md.). 1990, Vol 36, Num 6, pp 900-903, issn 0009-9147, 4 p.Article